Rhenman & Partners Asset Management Ab Axsome Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.01 Billion
- Q2 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 127,600 shares of AXSM stock, worth $11.4 Million. This represents 1.01% of its overall portfolio holdings.
Number of Shares
127,600
Previous 143,600
11.14%
Holding current value
$11.4 Million
Previous $11.5 Million
10.37%
% of portfolio
1.01%
Previous 1.12%
Shares
5 transactions
Others Institutions Holding AXSM
# of Institutions
289Shares Held
40.4MCall Options Held
365KPut Options Held
428K-
Rtw Investments, LP New York, NY4.63MShares$413 Million6.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$333 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$294 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$210 Million37.71% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.85MShares$165 Million4.89% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.82B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...